Method for breeding control in female bovines

• US 4,610,687 A
• Filed: 08/06/1984
• Issued: 09/09/1986
• Est. Priority Date: 08/06/1984
• Status: Expired due to Fees

• Current Assignee: The Board of Trustees of Michigan State University (Michigan State University)
• Original Assignee: The Board of Trustees of Michigan State University (Michigan State University)
• Inventors: Fogwell, Ralph L.
• Primary Examiner(s): GRIFFIN, RONALD
• Application Number:
  US06/638,044
• Time in Patent Office: 764 Days
• Field of Search: 514/173, 514/170, 514/169, 514/841, 604/890, 604/891
• US Class Current: 424/433
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L

Abstract

A method for reducing the time to estrus onset and duration of estrus in female bovines, is described. The method involves a sustained low level release of progestin over time with injection of a luteolytic agent, particularly a prostaglandin, towards the end of the time such that there is an overlap of progestin and prostaglandin administration. The sustained release is preferably by means of a vaginal implant. The method is faster and easier to use than prior art methods.

Claims

1. A method for fertile breeding control in female bovines comprising:

(a) establishing an estrus and ovulation blocking period of several days by continuous administrating of a progestin using an implant which slowly releases the progestin into the blood stream;

(b) injecting a luteolytic agent while continuing the administration of the progestin for a period of 1 to 6 days; and

(c) terminating the administration of the progestin, thereby allowing estrus and ovulation to occur in a shorter time period and in a relatively narrower time span than if administration of the progestin was terminated at the time of injection of the luteolytic agent.

2. The method of claim 1 wherein the progestin is progesterone.

3. The method of claim 2 wherein the progesterone is naturally occurring.

4. The method of claim 2 wherein the progesterone in the blood stream during and after injecting the luteolytic agent is between 1 to 2 nanograms per ml for at least about 1 day.

5. The method of claim 1 wherein the luteolytic agent is a prostaglandin.

6. The method of claim 5 wherein the prostaglandin is PGF₂ alpha.

7. The method of claim 1 wherein the progestin is released by means of a vaginal implant which provides a timed release of the progestin over a period of at least about 5 days prior to injecting the luteolytic agent.

8. The method of claim 1 wherein the implant is a vaginal implant which contains between about 0.5 and 2% by weight progesterone in timed release composition as the progestin and wherein the luteolytic agent is PGF₂ alpha which is injected in an amount of between about 20 and 30 mg into the blood stream of the bovine.

9. The method of claim 8 wherein the progesterone is about 2% by weight of the implant and the luteolytic agent is about 25 mg.

10. The method of claim 1 wherein progesterone as the progestin is continuously administered for about six (6) days, prostaglandin as the luteolytic agent is injected on the sixth day, the progestin administration is continued for three (3) more days and then the administration of progestin is terminated, thereby allowing estrus and ovulation to occur.